Neurol. praxi. 2025;26(4):332-336 | DOI: 10.36290/neu.2025.059

Tailored MS care: ocrelizumab among the pioneers of exposure-based treatment?

MUDr. Dominika Šťastná, Ph.D.^{1, 2}

¹ Neurologická klinika a Centrum klinických neurověd 1. LF UK a VFN v Praze

² Registr ReMuS, ReMuS, nadační fond, Praha

Multiple sclerosis treatment has advanced rapidly in recent years. One of the emerging trends is the individualisation of exposure to disease-modifying therapies. Available evidence indicates that patients with higher ocrelizumab exposure have a lower risk of confirmed disability progression compared to those with lower exposure. At the same time, it has been observed that in clinically stable patients, individually extended dosing intervals may help reduce the risk of adverse events and overall treatment burden. Personalised dosing thus appears to be a promising strategy for improving long-term outcomes. However, this approach requires careful monitoring and regular reassessment.

Keywords: multiple sclerosis, ocrelizumab, efficacy, safety, extended interval dosing, disease-modifying therapy, exposure, confirmed disease progression.

Received: June 9, 2025; Revised: July 12, 2025; Accepted: July 21, 2025; Prepublished online: July 21, 2025; Published: September 29, 2025  Show citation